Ipsen appoints Michelle C. Werner as EVP, President of North America

Core Viewpoint - Ipsen has appointed Michelle C. Werner as Executive Vice President and President of North America, effective March 23, 2026, to enhance its leadership team and drive growth in key therapeutic areas [1][2]. Group 1: Appointment Details - Michelle C. Werner will join Ipsen's Executive Leadership Team and report directly to CEO David Loew [1]. - She brings over 25 years of experience in the pharmaceutical industry, having held various leadership roles at companies such as Bristol Myers Squibb, AstraZeneca, and Novartis [3]. Group 2: Background and Experience - Prior to joining Ipsen, Michelle served as President and CEO of Alltrna since 2022 [3]. - Her career includes significant roles in sales, marketing, and global market access, particularly in oncology and rare diseases, which align with Ipsen's strategic focus [3]. Group 3: Transition and Impact - Michelle's appointment comes as Keira Driansky, the previous EVP and President for North America, departs to pursue external opportunities after two years of leading transformation and growth in U.S. sales [4]. - Michelle expressed enthusiasm about joining Ipsen at a pivotal moment for the company, emphasizing her passion for rare diseases and oncology [4]. Group 4: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, supported by nearly 100 years of development experience [5]. - The company operates in over 40 countries and partners globally to deliver medicines to more than 100 countries [5].